TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neumora Therapeutics, Inc. ( (NMRA) ) just unveiled an update.
On November 17, 2025, Neumora Therapeutics received a conversion notice from K2 HealthVentures, electing to convert $2.5 million of a term loan into common stock at a price of $0.8774 per share. Subsequently, on November 20, 2025, Neumora issued 2,849,327 shares to K2 HealthVentures Equity Trust LLC, utilizing a registration exemption under the Securities Act of 1933.
The most recent analyst rating on (NMRA) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Neumora Therapeutics, Inc. stock, see the NMRA Stock Forecast page.
Spark’s Take on NMRA Stock
According to Spark, TipRanks’ AI Analyst, NMRA is a Underperform.
Neumora Therapeutics, Inc. is significantly challenged by its financial position, with ongoing losses and no revenue. Technical analysis indicates bearish momentum, and valuation is difficult in the absence of earnings. While promising pipeline advancements and a strong cash position offer some optimism, the overall outlook is hindered by recent clinical setbacks and financial instability.
To see Spark’s full report on NMRA stock, click here.
More about Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. operates in the biotechnology industry, focusing on developing precision medicines for brain diseases.
Average Trading Volume: 1,431,754
Technical Sentiment Signal: Hold
Current Market Cap: $424.4M
See more data about NMRA stock on TipRanks’ Stock Analysis page.